- Report
- August 2024
- 77 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- April 2025
- 288 Pages
Global
From €5369EUR$5,600USD£4,486GBP
- Report
- January 2023
- 154 Pages
From €3307EUR$3,450USD£2,764GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
Primaquine is an antimalarial drug used to treat and prevent malaria caused by Plasmodium vivax and Plasmodium ovale. It is also used to treat infections caused by other protozoal parasites, such as Babesia microti and Toxoplasma gondii. Primaquine is a member of the 8-aminoquinoline class of drugs, which are known for their ability to inhibit the growth of malaria parasites. Primaquine is available in both oral and intravenous formulations, and is typically used in combination with other antimalarial drugs.
The Primaquine market is a rapidly growing segment of the Infectious Diseases Drugs market. Primaquine is increasingly being used to treat and prevent malaria in both endemic and non-endemic regions. The drug is also being used to treat other protozoal infections, such as Babesia microti and Toxoplasma gondii.
Companies in the Primaquine market include GlaxoSmithKline, Sanofi, Novartis, Pfizer, Merck, and Bayer. Show Less Read more